Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	2.41B
Revenue (ttm)	235.10M
Net Income (ttm)	-45.70M
Shares Out	16.59M
EPS (ttm)	-2.76
PE Ratio	n/a
Forward PE	96.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,147
Average Volume	20,642
Open	145.20
Previous Close	145.00
Day's Range	143.80 - 145.20
52-Week Range	83.30 - 159.40
Beta	0.77
RSI	45.67
Earnings Date	Nov 5, 2025

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analys...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 121
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2024, Devyser Diagnostics AB's revenue was 216.90 million, an increase of 28.12% compared to the previous year's 169.30 million. Losses were -61.50 million, 14.7% more than in 2023.